Skip to content

Construction and Optimization of a Diagnostic and Treatment System for Allergic Rhinitis-Asthma Syndrome Based on Zang-Xiang Theory and TCM Prevention and Treatment Strategies: A Study on the Intervention of Anserine Powder in the Preclinical Development of Allergic Rhinitis-Bronchial Asthma Syndrome

Construction of a diagnostic and therapeutic system for comorbid allergic rhinitis-asthma syndrome based on Zang-Xiang theory and optimization of preventive and therapeutic strategies in Traditional Chinese Medicine (TCM) research.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002520
Enrollment
Unknown
Registered
2025-12-24
Start date
2025-09-13
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis-Asthma Syndrome

Interventions

The Western medicine treatment group: 120 cases.:Cetirizine 10 mg oral at night for 2 weeks.
Integrated Traditional Chinese and Western Medicine Treatment Team:Phyllanthus urinaria powder, nasal application, bid + Cetirizine 10mg, oral administration at night for a 2-week course.

Sponsors

Zhejiang University of Traditional Chinese Medicine First Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Preclinical stage Meet the diagnostic criteria for AR and nasal disease; meet the diagnostic criteria for deficiency-cold of lung qi in traditional Chinese medicine; gender, age 18~75 years; asthmatic hyperresponsiveness positive (pulmonary function test/FeNO test); no other treatment used or treatment stopped for more than 2 weeks prior to enrollment; total nasal symptom score (TNSS) =4 points prior to enrollment; voluntarily participate in this clinical trial, voluntarily sign the informed consent, and willing to follow the study protocol.

Exclusion criteria

Exclusion criteria: (1) Patients who have progressed from AR to CARAS; (2) Patients with known allergies to any components of the drugs used in this study; (3) Patients with other nasal disorders, such as chronic rhinitis, paranasal sinusitis, nasal polyps, or deviated nasal septum; (4) Patients with notifiable infectious diseases, such as tuberculosis; (5) Patients with heart failure, moderate to severe hypertension, diabetes, other hematological diseases, or mental disorders who are unable to cooperate; (6) Patients in the pregnancy or lactation period, or those intending to become pregnant within the next 3 months.

Design outcomes

Primary

MeasureTime frame
The rate of recurrent acute episodes of AR within 1 year;Improvement in symptom scores (TNSS and TNNSS scores);

Secondary

MeasureTime frame
The incidence rate of progression to CARAS within 1 year.;

Countries

China

Contacts

Public ContactZHANG HONG

Zhejiang Provincial Hospital of Traditional Chinese Medicine (Affiliated First Hospital of Zhejiang University of Traditional Chinese Medicine)

hz.zhanghong@aliyun.com13588420208

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026